What is the Tisdale Risk Score?
The Tisdale Risk Score is a bedside additive model developed to estimate the likelihood that a hospitalized adult will develop clinically meaningful QT interval prolongation during the admission. It was designed for settings where multiple comorbidities, electrolyte shifts, and polypharmacy—especially QT-prolonging medications—overlap. The score does not diagnose arrhythmia; it helps teams prioritize medication reconciliation, electrolyte correction, and ECG surveillance when risk is higher.
Why QT prolongation matters in the hospital
The QT interval on the electrocardiogram reflects ventricular depolarization and repolarization. When repolarization is delayed, the corrected QT (QTc) may lengthen. In susceptible patients, marked prolongation increases vulnerability to torsades de pointes and other polymorphic ventricular tachycardias. Hospitalized patients often accumulate risk quickly: new antiemetics, antibiotics, antipsychotics, antiarrhythmics, or drug–drug interactions may be added; intravenous fluids, diuretics, and gastrointestinal losses may lower potassium or magnesium; and systemic illness can amplify hemodynamic or autonomic stress.
A structured risk estimate is useful because the underlying biology is multifactorial. The Tisdale score encodes several of the most reproducible, chart-accessible signals available at admission or early in the stay—demographics, selected diagnoses, admission QTc, serum potassium, loop diuretic exposure, and the count of QT-liability drugs—into a single total that maps to low, moderate, and high risk tiers.
What the score predicts
The score stratifies risk for development of QT prolongation during hospitalization in the populations studied in its derivation and validation work. Like other clinical prediction rules, it is most informative when used as decision support layered on top of indication-specific prescribing, allergy history, concomitant therapy, renal and hepatic function, and institutional pathways (pharmacy review, telemetry, electrolyte monitoring).
It should not be interpreted as a standalone mandate to start or stop therapy. Some patients with a low total score may still warrant caution if a high-risk drug is essential and no alternatives exist; conversely, a high score should trigger structured mitigation rather than automatic denial of care.
How the score is calculated
Each present factor contributes a fixed number of points. Points are summed to a maximum of 21. The medication-related items are structured so that exposure to one QT-prolonging drug contributes 3 points, while two or more contribute 6 points in total (reflecting the original weighting scheme: three points for the first agent and three additional points when multiple QT-liability agents overlap).
| Factor | Points |
|---|---|
| Age ≥68 years | 1 |
| Female sex | 1 |
| Loop diuretic on the admission medication list | 1 |
| One QT-prolonging drug on the admission medication list | 3 |
| Two or more QT-prolonging drugs on the admission medication list | 6 |
| Serum potassium ≤3.5 mEq/L (mmol/L) | 2 |
| Admission QTc ≥450 ms | 2 |
| Acute myocardial infarction | 2 |
| Heart failure with reduced ejection fraction | 3 |
| Sepsis | 3 |
Applying each criterion in practice
Age and sex
Advanced age and female sex are included as readily available demographic correlates of repolarization vulnerability in many cohorts. They are not pathognomonic; they simply adjust the prior probability that QTc will lengthen when other stressors appear.
Loop diuretics
Loop diuretics are scored when present on the admission medication list because they are associated with electrolyte loss and hemoconcentration of risk when combined with other QT-active drugs. Clinical teams should still interpret volume status, concurrent thiazides, and recent dosing changes, which may not be fully captured by a binary flag.
QT-prolonging medications
Count distinct agents with known QT liability on the admission list. Many institutions maintain formularies aligned with contemporary registries (for example, resources that classify agents by risk of torsades). Because lists evolve, periodic pharmacy-led updates are important. Combination products should be counted by their active moieties; duplicate entries of the same drug should not be double-counted.
Hypokalemia
Potassium ≤3.5 mEq/L (mmol/L) is scored because hypokalemia reduces repolarization reserve and synergizes with drug effects. Magnesium abnormalities, while not part of the original score, often co-travel with potassium disturbances and remain clinically relevant when managing torsades risk.
Admission QTc
An admission QTc ≥450 ms signals that repolarization is already prolonged before new hospital therapies are layered on. Serial ECGs may be appropriate when therapy changes, when risk factors accumulate, or when symptoms suggest arrhythmia.
Acute myocardial infarction, heart failure with reduced EF, and sepsis
These conditions reflect myocardial stress, autonomic activation, electrolyte shifts, and polypharmacy patterns common in acute care. They increase the chance that small additional QT stressors will produce a measurable change in repolarization during the admission.
Interpreting the total score
Risk increases monotonically with the total:
- Low risk: total score ≤6
- Moderate risk: total score 7–10
- High risk: total score ≥11
These bands describe relative strata in the original modeling framework. In clinical workflow, moderate and high strata often prompt a structured checklist: remove redundant QT drugs where possible, substitute lower-liability alternatives, correct potassium and magnesium, avoid additional interacting agents, and align monitoring intensity with patient acuity and institutional policy.
Using the score alongside medication safety workflows
Effective use typically involves multidisciplinary review. Pharmacists can reconcile high-yield interaction pairs, identify duplicate therapy, and propose dose adjustments in renal impairment. Cardiology input may be appropriate when QTc is markedly prolonged, when antiarrhythmic therapy is under consideration, or when risk-benefit is finely balanced. Nursing documentation of symptoms (syncope, palpitations) and telemetry events complements the numeric score.
Limitations and scope
The score was developed in hospitalized populations and may not generalize to outpatients, perioperative pathways, or pediatric patients. It does not incorporate every relevant modifier (genetics, magnesium, explicit interaction severity scores, or dynamic changes after admission). Scores should be recalculated when major clinical changes occur—new sepsis, new diuretic titration, or addition of QT-liability drugs mid-stay.
Finally, the tool supports risk communication and triage of safety tasks; it does not replace individualized medical judgment, shared decision-making, or local protocols for ECG monitoring and electrolyte replacement.